Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA Related Terms
China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA Chart
China Traditional Chinese Medicine Holdings Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Traditional Chinese Medicine Holdings Co Debt-to-EBITDA vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
China Traditional Chinese Medicine Holdings Co (STU:WSG) has a Debt-to-EBITDA of -5.10 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Traditional Chinese Medicine Holdings Co. According to the industry distribution chart, China Traditional Chinese Medicine Holdings Co ranks #999999 out of 692 companies in the Drug Manufacturers industry.
Is China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA too high?
China Traditional Chinese Medicine Holdings Co's current Debt-to-EBITDA is -5.10. Based on the distribution chart, China Traditional Chinese Medicine Holdings Co ranks #999999 out of 692 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Traditional Chinese Medicine Holdings Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does China Traditional Chinese Medicine Holdings Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Traditional Chinese Medicine Holdings Co ranks #999999 out of 692 companies for Debt-to-EBITDA. This places China Traditional Chinese Medicine Holdings Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Traditional Chinese Medicine Holdings Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Traditional Chinese Medicine Holdings Co's current Debt-to-EBITDA is -5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Traditional Chinese Medicine Holdings Co stock overvalued right now?
China Traditional Chinese Medicine Holdings Co (STU:WSG) has a current Debt-to-EBITDA of -5.10. The stock's GF Value™ is €0.45, compared to a current price of €0.22 — trading 51.1% below its estimated fair value. The current Debt-to-EBITDA is -5.10. China Traditional Chinese Medicine Holdings Co's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China Traditional Chinese Medicine Holdings Co (STU:WSG), the current Debt-to-EBITDA is -5.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Traditional Chinese Medicine Holdings Co (STU:WSG) Overvalued in 2026?
Based on GuruFocus' analysis, China Traditional Chinese Medicine Holdings Co stock appears to be undervalued.
The current stock price of €0.22 is trading 51.1% below its estimated GF Value™ of €0.45.
Key valuation signals for STU:WSG:
Debt-to-EBITDA: -5.10
GF Value™: €0.45 vs. price of €0.22 (51.1% below fair value)
No single metric tells the full story. See the STU:WSG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China, and also has its presence in Hong Kong and Other countries.
78GF Score
Get the complete analysis for STU:WSG
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:WSG has been successfully added to your 
